Biggest News Aggregation in the World
📰 William Cao News

William Cao News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from William Cao. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases - Gracell Biotechnologies (NASDAQ:GRCL)

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy
Cayman Islands United States Gracell Fas Harney Westwood Riegels Marvin Tang Jessica Laub Susan Galbraith

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across ...

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform
Cayman Islands United States William Cao Harney Westwood Riegels Gracell Fas Marvin Tang Jessica Laub

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in...
United States William Cao Gracell Biotechnologies Inc Fierce Life Sciences Innovation China National Medical Products Administration Exchange Commission

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells...
United States William Cao Drug Administration Exchange Commission Gracell Biotechnologies Inc Fierce Life Sciences Innovation

Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus

SAN DIEGO - Gracell Biotechnologies Inc. , a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and... | May 16, 2023
Marvin Tang William Cao Fierce Life Sciences Innovation Exchange Commission Gracell Biotechnologies Inc Chief Executive Officer

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science